ArticlePLoS pathogens2013
Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli.
Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 127 citations in OpenAlex.
- Colibactin produced by a honeybee gut symbiont mediates pathogen defence.Nature microbiology · 2026Article
- NLRP3 inflammasome partially mediates genotoxiciScience · 2026Article
- A genotoxin associated with colorectal cancer linked to gut dysbiosis in children with cystic fibrosis.Journal of bacteriology · 2026Article
- Genomic and phenotypic heterogeneity of Klebsiella aerogenes in a single host: plasmid loss and tissue-specific virulence gene expression during host adaptation.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Stage-Specific carcinogenic mechanisms and intervention strategies for pksArchives of microbiology · 2026Review
- From inflammation to fibrosis and cancer: the emerging role of AIEC-derived metabolites in intestinal disease progression.Experimental & molecular medicine · 2026Review
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- Host-derived nitrate fuels indole production byScience (New York, N.Y.) · 2026Article
- Selection, Comparative Genomics, and Potential Probiotic Features of Escherichia coli 5C, a pks-Negative Strain Isolated from Healthy Infant Donor Feces.Probiotics and antimicrobial proteins · 2026Article
- Colibactin produced by a honeybee symbiont defends against pathogens and shapes the gut community.bioRxiv : the preprint server for biology · 2025Article
- High polyketide synthase gene expression boosts pathogenicity of Klebsiella pneumoniae in the digestive infection.Scientific reports · 2025Article
- A genotoxin associated with colorectal cancer linked to gut dysbiosis in children with cystic fibrosis.bioRxiv : the preprint server for biology · 2025Article
- Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Nature reviews. Microbiology · 2025Review
- Whole-Genome Sequencing of Invasive Neonatal Escherichia coli From Uppsala County, Sweden.The Journal of infectious diseases · 2024Article
- A flow cytometry method for quantitative measurement and molecular investigation of the adhesion of bacteria to yeast cells.Scientific reports · 2024Article
- Interactions between diet and gut microbiota in cancer.Nature microbiology · 2024Review
- Clinical features and fecal microbiota characteristics of patients with both ulcerative colitis and axial spondyloarthritis.BMC gastroenterology · 2024Article
- Hypervirulent Klebsiella pneumoniae employs genomic island encoded toxins against bacterial competitors in the gut.The ISME journal · 2024Article
- The synthesis of the novelFrontiers in microbiology · 2024Review
- Yersiniabactin-ProducingInternational journal of molecular sciences · 2023Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Escherichia coli, the biosynthetic pathways of several small iron-scavenging molecules known as siderophores (enterobactin, salmochelins and yersiniabactin) and of a genotoxin (colibactin) are known to require a 4'-phosphopantetheinyl transferase (PPTase). Only two PPTases have been clearly identified: EntD and ClbA. The gene coding for EntD is part of the core genome of E. coli, whereas ClbA is encoded on the pks pathogenicity island which codes for colibactin. Interestingly, the pks island is physically associated with the high pathogenicity island (HPI) in a subset of highly virulent E. coli strains. The HPI carries the gene cluster required for yersiniabactin synthesis except for a gene coding its cognate PPTase. Here we investigated a potential interplay between the synthesis pathways leading to the production of siderophores and colibactin, through a functional interchangeability between EntD and ClbA. We demonstrated that ClbA could contribute to siderophores synthesis. Inactivation of both entD and clbA abolished the virulence of extra-intestinal pathogenic E. coli (ExPEC) in a mouse sepsis model, and the presence of either functional EntD or ClbA was required for the survival of ExPEC in vivo. This is the first report demonstrating a connection between multiple phosphopantetheinyl-requiring pathways leading to the biosynthesis of functionally distinct secondary metabolites in a given microorganism. Therefore, we hypothesize that the strict association of the pks island with HPI has been selected in highly virulent E. coli because ClbA is a promiscuous PPTase that can contribute to the synthesis of both the genotoxin and siderophores. The data highlight the complex regulatory interaction of various virulence features with different functions. The identification of key points of these networks is not only essential to the understanding of ExPEC virulence but also an attractive and promising target for the development of anti-virulence therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.